Graves' ophthalmopathy.
Bahn RS.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
Treatment of Graves' ophthalmopathy.
González-García A, Sales-Sanz M.
Med Clin (Barc). 2021 Feb 26;156(4):180-186. doi: 10.1016/j.medcli.2020.07.031. Epub 2020 Oct 14.
2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.
Hoang TD, Stocker DJ, Chou EL, Burch HB.
Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004. Epub 2022 May 11.
The risk factors for Graves' ophthalmopathy.
Cao J, Su Y, Chen Z, Ma C, Xiong W.
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1043-1054. doi: 10.1007/s00417-021-05456-x. Epub 2021 Nov 17.
Euthyroid Graves' ophthalmopathy.
Schattner A, Voichanski S, Pollack R, Uliel L.
QJM. 2023 Nov 24;116(11):942-943. doi: 10.1093/qjmed/hcad176.
Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM, Druce M, Ansari E.
BMJ Open Ophthalmol. 2024 Jun 17;9(1):e001515. doi: 10.1136/bmjophth-2023-001515.
Treatment of Graves' ophthalmopathy.
Alijotas-Reig J.
Med Clin (Barc). 2022 Jan 21;158(2):93. doi: 10.1016/j.medcli.2021.03.011. Epub 2021 Jun 16.
Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.
Li X, Li S, Fan W, Rokohl AC, Ju S, Ju X, Guo Y, Heindl LM.
Int Ophthalmol. 2023 Apr;43(4):1437-1449. doi: 10.1007/s10792-022-02537-6. Epub 2022 Oct 22.
Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML.
Front Endocrinol (Lausanne). 2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993. eCollection 2020.
A Review of Pathophysiology and Therapeutic Strategies Targeting TGF-beta in Graves' Ophthalmopathy.
Chang HH, Wu SB, Tsai CC.
Cells. 2024 Sep 5;13(17):1493. doi: 10.3390/cells13171493.
